Bacteriostatic Saline as a Local Anesthetic in Minor Eyelid Procedures

Summary

The investigators aim to assess whether bacteriostatic saline provides the same level of anesthesia as traditional local anesthesia while reducing pain associated with medication infusion in minor eyelid procedures

Conditions

• Eyelid Tumor
• Eyelid Bump
• Eyelid Deformity
• Eyelid Abscess
• Eyelid Boil
• Eyelid Papilloma
• Anesthesia, Local
• Ophthalmology

Interventions

DRUG

0.9% Bacteriostatic Local Anesthetic Injection

Following research and procedural consent, local anesthetic injection will be carried out using a standard 1 cc of local anesthetic corresponding to the study arm (0.9% bacteriostatic saline or 1% lidocaine with 1:100,000 epinephrine). Prior to anesthetic administration, the procedure site will be cleaned using standard measures. A 30 gauge needle on a 3 centimeter cubed volume syringe will be utilized. Five minutes will be given for local anesthetic to take effect.

DRUG

1% Lidocaine with 1:100,000 epinephrine Local Anesthetic Injection

Following research and procedural consent, local anesthetic injection will be carried out using a standard 1 cc of local anesthetic consisting of a commercially available mixture of 1% lidocaine with 1:100,000 epinephrine. Prior to anesthetic administration, the procedure site will be cleaned using standard measures. A 30 gauge needle on a 3 centimeter cubed volume syringe will be utilized. Five minutes will be given for local anesthetic to take effect.

PROCEDURE

Eyelid Lesion Removal

Following anesthesia administration, patient will proceed with recommended eyelid lesion removal. The procedure site will be cleaned according to standard protocol, and standard technique for lesion removal will be performed, which will vary according to type of lesion but may involve use of Westcott scissors, forceps, #15 or #11 blades or other oculoplastics administration. The exact procedural details will be at the discretion of the surgeon.

Sponsors & Collaborators

• University of California, San Francisco

  lead OTHER

Principal Investigators

• Robert Kersten, MD · University of California, San Francisco

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Model

PARALLEL

Eligibility

Min Age

18 Years

Max Age

110 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2022-05-17

Primary Completion

2023-02-21

Completion

2023-02-21

FDA Drug

Yes

Countries

• United States

Study Locations